Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from JMP Securities

JMP Securities Maintains Market Outperform Rating for DocuSign: Here's What You Need To Know

JMP Securities has decided to maintain its Market Outperform rating of DocuSign (NASDAQ:DOCU) and lower its price target from $180.00 to $151.00. Shares of DocuSign are trading down 24.11% over the last 24 hours, at $66.30 per share.

Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022

JMP Securities Maintains Market Outperform Rating for Goosehead Insurance: Here's What You Need To Know

JMP Securities has decided to maintain its Market Outperform rating of Goosehead Insurance (NASDAQ:GSHD) and lower its price target from $140.00 to $130.00. Shares of Goosehead Insurance are trading up 5.59% over the last 24 hours, at $55.66 per share.

Sprinklr Shares Gain As Analysts Hail Its Q4

Analysts mostly lifted their price targets on Sprinklr Inc (NYSE:CXM) following its Q4 beat. Sprinklr clocked Q4 FY21 revenue growth of 30% year-over-year to $135 million, beating the consensus of $130.38 million. Subscription revenue increased by 30.7% Y/Y to $117.69 million. "We accelerated our growth, went public, and created a new category called…

inkl

Read news from The Economist, FT, and more,
with one subscription

Crinetics' CRN04777 Shows Dose-Dependent Suppression of Fasting Insulin

Crinetics' CRN04777 Shows Dose-Dependent Suppression of Fasting Insulin

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) announced topline results from the multiple ascending dose (MAD) cohorts of healthy volunteers in the Phase 1 study of CRN04777. CRN04777 is a nonpeptide somatostatin receptor type 5 (SST5) agonist as an oral treatment for congenital monogenic and syndromic hyperinsulinism. This condition causes individuals to have abnormally high insulin…

Read Why JMP Securities Lowered Price Target On Rover Group

Read Why JMP Securities Lowered Price Target On Rover Group

JMP Securities analyst Ronald Josey lowered the price target on Rover Group Inc (NASDAQ:ROVR) to $11 (131% upside) from $15 and kept an Outperform rating on the shares post Q4 results. The analyst stated that omicron has increased cancellation rates in Q4 and impacted demand in Q1, limiting revenue visibility for 2022. In the longer…

Why Are Upwork Shares Trading Lower Today?

Why Are Upwork Shares Trading Lower Today?

JMP Securities analyst Andrew Boone lowered the price target on Upwork Inc (NASDAQ:UPWK) to $48 from $55 and maintained an Outperform rating on the shares after its in-line Q4 earnings and below-consensus outlook. The analyst mentions that the company is making substantial investments in the business while delaying profitability, now estimating 2022 EBITDA to be…

People

Bernie McTernan

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Maxar Technologies

Palantir Technologies

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play